Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash & Current Investments (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Cash & Current Investments for 6 consecutive years, with $96.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 59.56% to $96.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.2 million through Dec 2025, down 59.56% year-over-year, with the annual reading at $96.2 million for FY2025, 59.56% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $96.2 million at Lexicon Pharmaceuticals, down from $116.0 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $355.6 million in Q1 2024, with the low at $96.2 million in Q4 2025.
  • Average Cash & Current Investments over 3 years is $204.9 million, with a median of $206.6 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments soared 235.67% in 2024, then plummeted 59.56% in 2025.
  • Over 3 years, Cash & Current Investments stood at $170.0 million in 2023, then skyrocketed by 39.95% to $238.0 million in 2024, then tumbled by 59.56% to $96.2 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $96.2 million, $116.0 million, and $139.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.